C-terminal fragment of hGH studied in lipolysis research.
AOD-9604 is a modified C-terminal fragment of human growth hormone investigated for adipose research.
Mimics the lipolytic activity of hGH without engaging growth-related receptors in research models.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Compared AOD9604 with full-length hGH on adipose mobilization across wild-type and β3-AR knockout mice.
Significant fat mass reduction without altering food intake or lean body mass; effect preserved in β3-AR knockouts, suggesting non-β3 lipolytic pathway.
Pharmacokinetic and safety study of the hexadecapeptide in humans across escalating doses.
No serious adverse events, no impact on insulin sensitivity or IGF-1; supports GRAS designation.
Mapped the minimum lipolytic domain of hGH and characterized metabolic activity in adipose tissue preparations.
Localized lipolytic activity to the C-terminal fragment; established AOD-class peptides as receptor-divergent lipolytic agents.
Lyophilized -20°C, light-protected.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — AOD-9604 is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
